Key facts
- Developer of a medical diagnostic test designed for the early detection of Alzheimer's disease.
- It has raised $37.5M; the latest was Later Stage VC in Sep 2025.
- Notable investors include European Union, Clave (Pamplona), Alzheimers Drug Discovery Foundation, BStartup10, Capital Cell — 12 tracked in total.
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for ADmit Therapeutics
- ·The full record, as it builds
Create free account
No card required
Funding rounds
No rounds on record
No funding rounds for ADmit Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
About ADmit Therapeutics
Developer of a medical diagnostic test designed for the early detection of Alzheimer's disease. The company's diagnostic test is based on an epigenetic analysis in blood samples that covers methylcytosines with next-generation sequencing, enabling medical practitioners to identify Alzheimer's and accelerate the identification of curative drugs in a simplified way.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2017
- Employees
- 10
- Website
- admit-therapeutics.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
ADmit Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.